CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 230 enrolled
Drug / intervention
LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06381648
NCT06381648N/ACompleted

An Exosome-based Liquid Biopsy Signature for Pre-operative Identification of Lymph Node Metastasis in Patients With Intrahepatic Cholangiocarcinoma

City of Hope Medical Center·observational·Posted Apr 24, 2024·Updated Mar 13, 2026

In Brief

An observational study evaluating LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma) for Cholangiocarcinoma and 3 related conditions. Completed, enrolled 230 participants across 4 sites in 2 countries.

Detailed Summary

Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC. This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan, United States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedApr 24, 2024
Enrollment StartApr 15, 2023
Primary CompletionJun 1, 2025
Study CompletionJul 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 2.2 years ago

Interventions

LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)other

A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)